Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials

Phase 1 trials of molecularly targeted agents (MTA) often do not use toxicity data beyond the first cycle of treatment to determine a recommended phase 2 dose (RP2D). We investigated the potential utility of longitudinal relative dose intensity (RDI) that may be a better new way of determining a mor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Hirakawa, Akihiro, Yonemori, Kan, Kinoshita, Fumie, Kobayashi, Yumiko, Okuma, Hitomi S., Kawachi, Asuka, Tamura, Kenji, Fujiwara, Yasuhiro, Rubinstein, Larry, Harris, Pamela Jo, Takebe, Naoko
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765308/
https://ncbi.nlm.nih.gov/pubmed/29114963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13436
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados